

2




Patients in the UK experience a high prevalence of poor asthma control.<sup>4</sup>

Asthma exacerbations are a major cause of disease morbidity, rises in healthcare costs, and for some patients, a greater progressive loss of lung function.<sup>5</sup>

The frequency of these exacerbations can be reduced through treatments such as ICS/LABAs.<sup>5</sup> Though, even with ICS/LABA therapy, 30–50% of patients with moderate or severe asthma remain inadequately controlled.<sup>6</sup>



Loss of lung  
function



Morbidity



Healthcare  
costs



30–50%  
of patients



## Co-primary endpoints:<sup>10</sup>

Compared with Fostair pMDI 100/6,  
over 52 weeks Trimbow pMDI 87/5/9  
delivered a:




reduction in the rate of moderate  
and severe exacerbations

(Annualised rate: 1.83 vs. 2.16 respectively  
[ARR 0.33, RR 0.85, p=0.033])



## Primary endpoint:<sup>11</sup>

Compared with Ultibro<sup>®</sup> Breezhaler<sup>®</sup>,  
Trimbow pMDI 87/5/9 delivered a:



reduction in the rate of moderate  
to severe exacerbations

(ARR 0.09, RRR 15%, p=0.043)

Compared with Fostair pMDI 100/6,  
at week 26 Trimbow pMDI 87/5/9  
delivered a:




improvement in  
pre-dose morning FEV<sub>1</sub>

(Change from baseline: 185 mL vs. 127 mL  
respectively [p=0.008])



## Primary endpoint:

Compared with Spiriva® HandiHaler® alone, over 52 weeks Trimbow pMDI 87/5/9 delivered a:




reduction in the rate of moderate to severe exacerbations<sup>9</sup>

(p=0.0025; ARR 0.11)



## Key secondary endpoint:

Compared with Fostair pMDI 100/6,  
Trimbow pMDI 87/5/9 delivered a:<sup>10</sup>



reduction in rate of moderate  
to severe exacerbations

(ARR 0.12, RRR 23%, p=0.005)



It is estimated that 3 million people in the UK have COPD.<sup>4</sup>



COPD exacerbations that require hospital admission have important clinical implications.<sup>5</sup>





